1-11 of 11
Rodrigo Santucci Silva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Renato Torrescasana Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Daniela Ferreira Dias, Israel Bendit, Jhony ARANHA Lima Alves, Felipe Ribeiro Bruniera, Ariel Testasicca Trunkel, Adelson Alves da Silva, Sr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 12226–12227.
https://doi.org/10.1182/blood-2022-157425
Published: 2022
Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Renato Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Joyce Barreto Marques da Rosa Ferreira, Iohanã Gabriely Costa Oliveira, Luana Correa Travassos, Caroline Jorge Espadas, Tamyres Alves Gomes, Mariana Nascimento Caiaffo Rodrigues, Adelson Alves Silva
Journal: Blood
Blood (2022) 140 (Supplement 1): 7954–7955.
https://doi.org/10.1182/blood-2022-157148
Published: 2022
Journal Articles

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Guilherme Brasil Duffles Amarante, MD, Valeria Buccheri, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-142810
Published: 2020
Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Wellington F Silva, MD, Valeria Buccheri, Alita Azevedo, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Laura Maria Fogliatto, MD PhD, Leila Martins Perobelli, MD, Glaciano Ribeiro, MD, Germison Silva Lopes, Vera Lucia de Piratininga Figueiredo, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-142520
Published: 2020
Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5847.
https://doi.org/10.1182/blood-2019-128629
Published: 2019
Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1764.
https://doi.org/10.1182/blood-2019-125626
Published: 2019
Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid
Journal: Blood
Blood (2018) 132 (Supplement 1): 394.
https://doi.org/10.1182/blood-2018-99-111248
Published: 2018
Journal Articles

Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

Shana Traina, PhD, Graeme Fraser, MDFRCPC, Paula Cramer, MD, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Marie Sarah Dilhuydy, MD, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD
Journal: Blood
Blood (2015) 126 (23): 267.
https://doi.org/10.1182/blood.V126.23.267.267
Published: 2015
Journal Articles

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Asher Chanan-Khan, MD, Paula Cramer, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Aleksander Pristupa, MD, Marie Sarah Dilhuydy, MD, Andre Goy, MD, Anthony R. Mato, MD MSCE, Rajendra Damle, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Angela Howes, PhD, Sriram Balasubramanian, PhD
Journal: Blood
Blood (2015) 126 (23): 1732.
https://doi.org/10.1182/blood.V126.23.1732.1732
Published: 2015
Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Paula Cramer, MD, Asher Chanan-Khan, MD, Graeme Fraser, MDFRCPC, Fatih Demirkan, MD, Rodrigo Santucci Silva, MD, Halyna Pylypenko, MD, Sebastian Grosicki, MD PhD, Ann Janssens, MD, Andre Goy, MD, Jiri Mayer, Prof., MD, Marie Sarah Dilhuydy, MD, Javier Loscertales, MD PhD, Nancy L. Bartlett, MD, Abraham Avigdor, MD, Simon Rule, MD, Steven Sun, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Sriram Balasubramanian, PhD, Angela Howes, PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 2938.
https://doi.org/10.1182/blood.V126.23.2938.2938
Published: 2015
Journal Articles

Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Asher Chanan-Khan, MD, Paula Cramer, MD, Fatih Demirkan, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Halyna Pylypenko, MD, Sebastian Grosicki, MD PhD, Ann Janssens, MD, Aleksander Pristupa, MD, Andre Goy, MD, Jiri Mayer, Prof., MD, Marie Sarah Dilhuydy, MD, Javier Loscertales, MD PhD, Nancy L. Bartlett, MD, Abraham Avigdor, MD, Simon Rule, MD, Steven Sun, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 2936.
https://doi.org/10.1182/blood.V126.23.2936.2936
Published: 2015